US medical societies launch new hepatitis C treatment guidelines
Gilead two-drug hep C combination cures 94% of genotype 1 patients in eight weeks
Faldaprevir effective across patient sub-groups with several baseline characteristics associated with treatment outcomes
Faldaprevir safe and effective in HCV treatment-experienced patients
AbbVie reports 96% cure rate for interferon-free hepatitis C regimen in phase 3 study
Sofosbuvir/ribavirin for 24 weeks cures most genotype 3 hepatitis C patients, adding interferon may help difficult-to-treat
Faldaprevir plus pegylated interferon/ribavirin leads to early sustained response in people with HIV and HCV co-infection
Daclatasvir + asunaprevir cures 85% of genotype 1b hepatitis C patients in Japanese study
Fixed-dose sofosbuvir/ledipasvir with or without ribavirin cures most genotype 1 hepatitis C patients, LONESTAR study shows
